Publications by authors named "R Donovick"
Article Synopsis
- The study examines the effectiveness of buprenorphine treatment for opioid dependence across three different settings: an opioid treatment program (OTP), a group counseling program using the Matrix Model, and a private psychiatrist clinic.
- Participants received a year-long buprenorphine treatment, with varied treatment visit schedules, and outcomes were measured based on opioid use, retention in treatment, and participation in counseling.
- Results indicated that while opioid use was consistent across sites, retention rates differed significantly depending on the treatment setting, pointing to the effectiveness of the environment in supporting participant engagement.
Aims: In order to increase the number of investigative teams and sites conducting research on pharmacological treatments for methamphetamine use disorders, the National Institute on Drug Abuse (NIDA) established an infrastructure of clinical sites in areas where methamphetamine addiction is prevalent. This multi-site infrastructure would serve to run multiple Phases II and III protocols effectively and expeditiously.
Methods: NIDA collaborated with investigators from the University of California at Los Angeles (UCLA) to set up the Methamphetamine Clinical Trials Group (MCTG).
Alvimopan has been shown to reverse the inhibitory effect of opioids on gastrointestinal transit without affecting analgesia. We evaluated oral alvimopan, 0.5 or 1 mg, versus placebo, once daily for 21 days, in 168 patients with opioid-induced bowel dysfunction (OBD) who were receiving chronic opioid therapy (minimum, 1 month) for nonmalignant pain (n = 148) or opioid dependence (n = 20).
View Article and Find Full Text PDF